Fate Therapeutics Inc (NASDAQ:FATE) shares, rose in value on Wednesday, April 16, with the stock price down by -6.25% to the previous day’s close as strong demand from buyers drove the stock to $1.05.
Actively observing the price movement in the last trading, the stock closed the session at $1.12, falling within a range of $1.03 and $1.18. The value of beta (5-year monthly) was 2.415. Referring to stock’s 52-week performance, its high was $5.92, and the low was $0.66. On the whole, FATE has fluctuated by 14.07% over the past month.
With the market capitalization of Fate Therapeutics Inc currently standing at about $120.34 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-04.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.18M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FATE’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of FATE currently trading nearly 17.62% and -0.98% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.92, while the 7-day volatility ratio is showing 19.56% which for the 30-day chart, stands at 12.67%. Furthermore, Fate Therapeutics Inc (FATE)’s beta value is 2.21, and its average true range (ATR) is 0.13.
A comparison of Fate Therapeutics Inc (FATE) with its peers suggests the former has fared considerably weaker in the market. FATE showed an intraday change of -6.25% in last session, and over the past year, it shrunk by -81.38%%.
Data on historical trading for Fate Therapeutics Inc (NASDAQ:FATE) indicates that the trading volumes over the past 10 days have averaged 2.51 and over the past 3 months, they’ve averaged 2.22 million. According to company’s latest data on outstanding shares, there are 113.93 million shares outstanding.
Nearly 9.70% of Fate Therapeutics Inc’s shares belong to company insiders and institutional investors own 84.86% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 16.37 million shares as on 2025-03-31, resulting in a short ratio of 7.52. According to the data, the short interest in Fate Therapeutics Inc (FATE) stood at 1638.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 13.33 million. The stock has fallen by -36.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FATE stock heading into the next quarter.
